Hanall Biopharma & Daewoong Pharmaceutical announce U.S. Phase II clinical trial of new dry eye therapy
On the 29th, Hanall Biopharma and Daewoong Pharmaceutical announced their U.S. Phase II clinical trial(a.k.a. Topline) result of the dry eye treatment biosimilar HL036 that they are jointly developing. The Phase II clinical trial was conducted at 2 ophthalmic clinical trial centers in Boston thro...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
